727 related articles for article (PubMed ID: 36646686)
1. Targeted therapy for head and neck cancer: signaling pathways and clinical studies.
Li Q; Tie Y; Alu A; Ma X; Shi H
Signal Transduct Target Ther; 2023 Jan; 8(1):31. PubMed ID: 36646686
[TBL] [Abstract][Full Text] [Related]
2. Prognostic signature associated with radioresistance in head and neck cancer via transcriptomic and bioinformatic analyses.
You GR; Cheng AJ; Lee LY; Huang YC; Liu H; Chen YJ; Chang JT
BMC Cancer; 2019 Jan; 19(1):64. PubMed ID: 30642292
[TBL] [Abstract][Full Text] [Related]
3. RTKs in pathobiology of head and neck cancers.
Nadhan R; Srinivas P; Pillai MR
Adv Cancer Res; 2020; 147():319-373. PubMed ID: 32593405
[TBL] [Abstract][Full Text] [Related]
4. Photodynamic therapy with 5-aminolevulinic acid (ALA) impairs tumor initiating and chemo-resistance property in head and neck cancer-derived cancer stem cells.
Yu CH; Yu CC
PLoS One; 2014; 9(1):e87129. PubMed ID: 24475244
[TBL] [Abstract][Full Text] [Related]
5. Cancer stem cells in head and neck cancer: A Mini Review.
Silva Galbiatti-Dias AL; Pavarino ÉC; Kawasaki-Oyama RS; Maniglia JV; Maniglia EJ; Goloni Bertollo EM
Cell Mol Biol (Noisy-le-grand); 2015 Oct; 61(6):39-43. PubMed ID: 26518895
[TBL] [Abstract][Full Text] [Related]
6. Investigational drugs for head and neck cancer.
Bossi P; Alfieri S
Expert Opin Investig Drugs; 2016 Jul; 25(7):797-810. PubMed ID: 27054910
[TBL] [Abstract][Full Text] [Related]
7. Novel Systemic Treatment Modalities Including Immunotherapy and Molecular Targeted Therapy for Recurrent and Metastatic Head and Neck Squamous Cell Carcinoma.
Ghosh S; Shah PA; Johnson FM
Int J Mol Sci; 2022 Jul; 23(14):. PubMed ID: 35887235
[TBL] [Abstract][Full Text] [Related]
8. The Association Between Computed Tomography-Defined Sarcopenia and Outcomes in Adult Patients Undergoing Radiotherapy of Curative Intent for Head and Neck Cancer: A Systematic Review.
Findlay M; White K; Lai M; Luo D; Bauer JD
J Acad Nutr Diet; 2020 Aug; 120(8):1330-1347.e8. PubMed ID: 32711854
[TBL] [Abstract][Full Text] [Related]
9. Targeting HER (ERBB) signaling in head and neck cancer: An essential update.
Zhang J; Saba NF; Chen GZ; Shin DM
Mol Aspects Med; 2015 Nov; 45():74-86. PubMed ID: 26163475
[TBL] [Abstract][Full Text] [Related]
10. Immunotherapy Advances in Locally Advanced and Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma and Its Relationship With Human Papillomavirus.
Wang H; Zhao Q; Zhang Y; Zhang Q; Zheng Z; Liu S; Liu Z; Meng L; Xin Y; Jiang X
Front Immunol; 2021; 12():652054. PubMed ID: 34305889
[TBL] [Abstract][Full Text] [Related]
11. Portrait of DNA methylated genes predictive of poor prognosis in head and neck cancer and the implication for targeted therapy.
Hier J; Vachon O; Bernstein A; Ibrahim I; Mlynarek A; Hier M; Alaoui-Jamali MA; Maschietto M; da Silva SD
Sci Rep; 2021 May; 11(1):10012. PubMed ID: 33976322
[TBL] [Abstract][Full Text] [Related]
12. Aurora kinases are a novel therapeutic target for HPV-positive head and neck cancers.
Shaikh MH; Idris A; Johnson NW; Fallaha S; Clarke DTW; Martin D; Morgan IM; Gabrielli B; McMillan NAJ
Oral Oncol; 2018 Nov; 86():105-112. PubMed ID: 30409290
[TBL] [Abstract][Full Text] [Related]
13. Identifying potential prognostic biomarkers in head and neck cancer based on the analysis of microRNA expression profiles in TCGA database.
Wang X; Yin Z; Zhao Y; He M; Dong C; Zhong M
Mol Med Rep; 2020 Mar; 21(3):1647-1657. PubMed ID: 32016476
[TBL] [Abstract][Full Text] [Related]
14. Advances in Head and Neck Cancer Pain.
Ye Y; Jensen DD; Viet CT; Pan HL; Campana WM; Amit M; Boada MD
J Dent Res; 2022 Aug; 101(9):1025-1033. PubMed ID: 35416080
[TBL] [Abstract][Full Text] [Related]
15. Current Insights and Progress in the Clinical Management of Head and Neck Cancer.
Amaral MN; Faísca P; Ferreira HA; Gaspar MM; Reis CP
Cancers (Basel); 2022 Dec; 14(24):. PubMed ID: 36551565
[TBL] [Abstract][Full Text] [Related]
16. Nanoparticle therapy for head and neck cancers.
Hoffmann C; Shen C; Le Tourneau C
Curr Opin Oncol; 2022 May; 34(3):177-184. PubMed ID: 35249962
[TBL] [Abstract][Full Text] [Related]
17. Suppression of Aurora-A-FLJ10540 signaling axis prohibits the malignant state of head and neck cancer.
Chen CH; Chang AY; Li SH; Tsai HT; Shiu LY; Su LJ; Wang WL; Chiu TJ; Luo SD; Huang TL; Chien CY
Mol Cancer; 2015 Apr; 14():83. PubMed ID: 25889801
[TBL] [Abstract][Full Text] [Related]
18. Management of head and neck cancer in elderly patients.
Lalami Y; de Castro G; Bernard-Marty C; Awada A
Drugs Aging; 2009; 26(7):571-83. PubMed ID: 19655824
[TBL] [Abstract][Full Text] [Related]
19. MEK1/2 inhibition transiently alters the tumor immune microenvironment to enhance immunotherapy efficacy against head and neck cancer.
Prasad M; Zorea J; Jagadeeshan S; Shnerb AB; Mathukkada S; Bouaoud J; Michon L; Novoplansky O; Badarni M; Cohen L; Yegodayev KM; Tzadok S; Rotblat B; Brezina L; Mock A; Karabajakian A; Fayette J; Cohen I; Cooks T; Allon I; Dimitstein O; Joshua B; Kong D; Voronov E; Scaltriti M; Carmi Y; Conde-Lopez C; Hess J; Kurth I; Morris LGT; Saintigny P; Elkabets M
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35292516
[TBL] [Abstract][Full Text] [Related]
20. DNA Damage Response Mechanisms in Head and Neck Cancer: Significant Implications for Therapy and Survival.
Papalouka C; Adamaki M; Batsaki P; Zoumpourlis P; Tsintarakis A; Goulielmaki M; Fortis SP; Baxevanis CN; Zoumpourlis V
Int J Mol Sci; 2023 Feb; 24(3):. PubMed ID: 36769087
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
